Micro Developing Active

LLY GLP-1フランチャイズ成長

スコア
0.5
勢い
▲ 0.0
記事
13
情報源
4

サマリー

この物語に属する記事は、Eli LillyのGLP-1 franchise drugsの成長について報告するものである。

関連記事

US approves new oral weight-loss pill developed by Eli Lilly

The Guardian · 4月 02, 2026
Mixed

Why Eli Lilly Stock Trounced the Market Today

Nasdaq · 4月 01, 2026
Mixed

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Nasdaq · 3月 27, 2026
Mixed

情報源

US approves new oral weight-loss pill developed by Eli Lilly The Guardian
Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You … Yahoo Finance
Why Eli Lilly Stock Trounced the Market Today Nasdaq
FDA approves Eli Lilly's GLP-1 pill, opening the next phase … CNBC
Eli Lilly and Company (LLY) Continued to Gain from Its … Yahoo Finance
Eli Lilly’s (LLY) Shares Up Since Jim Cramer Said He … Yahoo Finance
GSK (GSK) Shares Up Significantly Since Jim Cramer Said to … Yahoo Finance
Mounjaro maker wants NHS drug price rises in return for … The Guardian
Jefferies Remains a Buy on Eli Lilly and Company (LLY) Yahoo Finance
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is … Nasdaq
Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 … Nasdaq
Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises … Yahoo Finance

タイムライン

最終更新 3月 27, 2026